Ask Warren

Reyon Pharmaceutical

102460 · KOSPI · ₩102460 · 이연제약

₩9,370▲ ₩10 (0.11%)End-of-day · Oct 30, 2026 · End-of-day prices.
Trade
Alert me
SellBuy
AnnualQuarterly

Income statement

Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024
Revenue₩36B₩36B₩34B₩38B₩38B₩37B₩37B₩38B
Cost of sales₩27B₩26B₩26B₩27B₩32B₩23B₩19B₩20B
Gross profit₩9.3B₩9.8B₩8.2B₩10B₩6B₩14B₩18B₩19B
Operating income−₩7B−₩6.7B−₩8.2B−₩7.2B−₩11B−₩3.8B−₩3B₩1.7B
Net income₩3.9B−₩11B−₩26B₩9.3B−₩13B₩216M₩3.5B−₩366M
Net income to shareholders−₩6.8B−₩11B−₩13B−₩3.9B−₩13B₩216M₩2.5B₩619M

Balance sheet

Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024
Total assets₩444B₩454B₩465B₩473B₩476B₩490B₩500B₩495B
Current assets₩79B₩77B₩80B₩82B₩80B₩86B₩89B₩82B
Cash and equivalents₩7B₩4.3B₩6.7B₩8.5B₩8.6B₩8.8B₩10B₩6.4B
Total liabilities₩250B₩245B₩245B₩240B₩239B₩240B₩250B₩247B
Current liabilities₩158B₩148B₩143B₩136B₩131B₩127B₩136B₩131B
Borrowings₩90B₩95B₩99B₩103B₩107B₩93B₩89B₩150B
Total equity₩195B₩210B₩220B₩233B₩237B₩250B₩250B₩247B
Shareholders' equity₩195B₩210B₩220B₩233B₩237B₩250B₩250B₩247B

Cash flow

Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024
Cash from operations₩8.9B−₩2.4B₩1.5B−₩1.7B−₩678M₩2.4B−₩5.3B₩1.8B
Capital spending−₩894M−₩1.2B−₩2B−₩989M−₩9.2B₩4.2B−₩34B₩30B
Free cash flow₩8B−₩3.6B−₩531M−₩2.7B−₩9.9B−₩1.8B−₩39B−₩28B
Dividends paid——₩0₩0——₩0₩0

Consolidated where available. Amounts in won.

Also known as: Reyon Pharmaceutical / 이연제약 / 102460 / KRX:102460

Source: KRX statistical information